Therapeutic Story-Souvenirs to remind the child of the story they have created. Online guidelines for therapists provide prompts for using the stories and suggestions on how to use the resources.
Author: Angela Amos
Category: Child psychotherapy
"Therapeutic Story StartUps is a creative resource that can be used by therapists and other professionals working with children aged 4-12 years. They are designed to support children to understand, explore and express their feelings through story imagination and play. Six beautifully illustrated storybooks address themes of: Loss, Bullying, Anger, Worries, Family Break-Up and low Self-Esteem. The accompanying characters, props and scenes invite the child to act out their own story, asking the question, "What happens next?... " The full pack includes: - Six illustrated storybooks, each prompting the child to create their own ending. - 30 colourful free-standing characters, six background scenes and a number of additional props. - Six mood-cards designed to support story-making. - Therapeutic Story-Souvenirs to remind the child of the story they have created. - Online guidelines for therapists provide prompts for using the stories and suggestions on how to use the resources. Separate guidelines for non-therapists are also provided"--
The Forgotten Cure traces the story of phages from Paris, where they were discovered in 1917; to Tbilisi, Georgia, where one of phage therapy’s earliest proponents died at the hands of Stalin; to the Nobel podium, where prominent ...
Author: Anna Kuchment
Publisher: Springer Science & Business Media
Before the arrival of penicillin in the 1940s, phage therapy was one of the few weapons doctors had against bacterial infections. It saved the life of Hollywood legend Tom Mix before being abandoned by Western science. Now, researchers and physicians are rediscovering the treatment, which pits phage viruses against their natural bacterial hosts, as a potential weapon against antibiotic-resistant infections. The Forgotten Cure traces the story of phages from Paris, where they were discovered in 1917; to Tbilisi, Georgia, where one of phage therapy’s earliest proponents died at the hands of Stalin; to the Nobel podium, where prominent scientists have been recognized for breakthroughs stemming from phage research. Today, a crop of biotech startups and dedicated physicians is racing to win regulatory approval for phage therapy before superbugs exhaust the last drug in the medical arsenal. Will they clear the hurdles in time?
... door to local startups , giving young entrepreneurs access to university labs ,
equipment , and classes . Fitzsimons has already graduated one success story —
Myogen , which develops therapeutic drugs for treating cardiovascular disease .
A Story of Biotechnology Paul Rabinow. tions, and potential therapeutic utility. ...
Finally, Kenney points to the key role of senior scientists in startup companies as
the vital communication link between corporate management (and the scientific ...
Author: Paul Rabinow
Publisher: University of Chicago Press
Making PCR is the fascinating, behind-the-scenes account of the invention of one of the most significant biotech discoveries in our time—the polymerase chain reaction. Transforming the practice and potential of molecular biology, PCR extends scientists' ability to identify and manipulate genetic materials and accurately reproduces millions of copies of a given segment in a short period of time. It makes abundant what was once scarce—the genetic material required for experimentation. Making PCR explores the culture of biotechnology as it emerged at Certus Corporation during the 1980s and focuses on its distinctive configuration of scientific, technical, social, economic, political, and legal elements, each of which had its own separate trajectory over the preceding decade. The book contains interviews with the remarkable cast of characters who made PCR, including Kary Mullin, the maverick who received the Nobel prize for "discovering" it, as well as the team of young scientists and the company's business leaders. This book shows how a contingently assembled practice emerged, composed of distinctive subjects, the site where they worked, and the object they invented. "Paul Rabinow paints a . . . picture of the process of discovery in Making PCR: A Story of Biotechnology [and] teases out every possible detail. . . . Makes for an intriguing read that raises many questions about our understanding of the twisting process of discovery itself."—David Bradley, New Scientist "Rabinow's book belongs to a burgeoning genre: ethnographic studies of what scientists actually do in the lab. . . . A bold move."—Daniel Zalewski, Lingua Franca "[Making PCR is] exotic territory, biomedical research, explored. . . . Rabinow describes a dance: the immigration and repatriation of scientists to and from the academic and business worlds."—Nancy Maull, New York Times Book Review
for delayed home purchases, failure to obtain proper medical care, and deferring
small business startups.23 The whole time I was working on Maria Elena's
narrative, I was also thinking of Mary Robinson and the stories that she told when
we were together. Although it ... I found the process immensely therapeutic. The
Author: Fran Leeper Buss
Publisher: University of Michigan Press
A pioneering oral historian analyzes recurring themes in the lives of poor and working-class women
11 Rima Marrouch , “ Syria ' s Post - Uprising Media Outlets : Challenges and
Opportunities in Syrian Radio Startups ... 23 “ A New Radio Soap Opera Gives
Syrian Refugees a chance to Tell Their Own Story , ” The Takeaway , https ... For
a discussion of the Syrian Trojan women , see Edward Ziter , “ The Syrian Trojan
Women : Rethinking the Public with Therapeutic Theater , ” Communication and
Author: Babak Rahimi
Publisher: Anthem Press
The collected essays from noteworthy dramatists and scholars in this book represent new ways of understanding theater in the Middle East not as geographical but transcultural spaces of performance. What distinguishes this book from previous works is that it offers new analysis on a range of theatrical practices across a region, by and large, ignored for the history of its dramatic traditions and cultures, and it does so by emphasizing diverse performances in changing contexts. Topics include Arab, Iranian, Israeli, diasporic theatres from pedagogical perspectives to reinvention of traditions, from translation practices to political resistance expressed in various performances from the nineteenth century to the present.
million a year for gene - therapy research , and big pharma - to be injected
intravenously . The FDA had subsequently ceutical firms and swarms of
biotechnology startups were authorized direct injection of the vector into the
hepatic thought to be spending as much again , not a single suc ... Inserting a
Gene 2006 TAMIJ 44 TECHNOLOGY REVIEW NOVEMBER / DECEMBER 2006
Description: Canada's venture capital center has become a hotbed of technology startups because of the unique incentives, including tax ... Description:
Agricultural biotechnology's third wave, producing therapeutic proteins from
plants, should help the beleaguered field improve its public image. ... 47711 □ "
Before You Do That 'Amazing' Biotech Deal, Read This Story" in Venture Capital
Two - thirds of diagnostic and therapeutic companies reported lower net income
or greater losses . ... These are sobering statistics , but they have to be
considered in light of other statistics that tell a very different story . ... Diversified
Financing Reduces the Impact of the Crash After their first few years as green startups , typically funded by venture capital and private equity , biotech
companies learn to ...
... Somehow , the story caught on 260,000 shares of its cora by Sector in 2000
winning regions in a competi- and more journalists jumped on and extinguish
any recen tion . ... BSC's paclitaxel - elu a clinical development consultancy
German States , the approval effi startups . ... Manufacturing Your centre of
excellence in managing the manufacture of therapeutic Antibody based
therapeutics and antibody ...
98 at 19 ) and its lead product , NEX41 , is a therapeutic protein with a market
potential considered large . ... development of its NEX41 product , to expand its
farm , and begin research and development in the field of biofilaments ( see story
, page 16 ) . ... The Burrill Agbio Capital Fund was established to invest in new
companies at a time when there is a distinct shortage of innovative agbio startups
The impact of technology transfer can be seen in the stories of the products ,
services and relationships created with U - M innovations . A new U - M startup ,
Zattoo , is developing a global virtual cable network to bring live TV via the
Internet . Known as peer - to ... This discovery , which holds promise as both a
diagnostic and a therapeutic , has been licensed to Baxter Pharmaceuticals .
Creating An ...
... in have to make that investment before new startups are still being financed “ I
am personally extremely fact , occupying a leading - edge ... A new angioplasty therapeutic called ReoPro will likely receive which is a 20 percent increase in
tion " strategy - being adopted by ... They point to a 27 percent value of the
product or its spon story ) . organization , created regional sales offices around
the world - all ...
... Times that the national leadership should convert many of the military bases
into therapeutic communities to treat the victims of the drug war . ... Sabin Russell
, “ New Biotech Brainstorm : Startups Are Vying for a Piece of the Huge
Neurobiological Drug Market , " San Francisco ... Joan O'C . Hamilton , et al . , “
Cover Story ...
Meanwhile , new genetic and reproductive technologies were burgeoning ,
biotech startups were raking in investment capital , and an extreme ... According
to a report last year in Nature , “ many experts do not now expect therapeutic
cloning to have a large clinical impact ” ( Peter Aldhous ... A recent story in the
Los Angeles Times ' business section puts this conclusion in dollars - and - cents